Literature DB >> 12122745

The immunology of inflammatory bowel disease.

Scott Plevy1.   

Abstract

The dogma of systemic immunity can be ignored in relation to mucosal immunity. These distinct immune systems evolved based on specific environmental realities. Given the potentially hostile environment encountered by the mucosal immune system, it is a necessary adaptation that the overall tone is one of suppression. Breaches in this tone may lead to chronic inflammation. Understanding how specific components and processes of the mucosal immune system interact with the environment will elucidate the pathogenesis of IBD and lead to novel therapeutic approaches.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12122745     DOI： 10.1016/s0889-8553(01)00006-1

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN： 0889-8553            Impact factor:   3.806


  8 in total

Review 1.  The role of adipose stem cells in inflammatory bowel disease: From biology to novel therapeutic strategies.

Authors:  Francesco De Francesco; Maurizio Romano; Laura Zarantonello; Cesare Ruffolo; Daniele Neri; Nicolò Bassi; Antonio Giordano; Giacomo Zanus; Giuseppe A Ferraro; Umberto Cillo
Journal:  Cancer Biol Ther       Date:  2016-07-14       Impact factor: 4.742

2.  IL-10 regulates Il12b expression via histone deacetylation: implications for intestinal macrophage homeostasis.

Authors:  Taku Kobayashi; Katsuyoshi Matsuoka; Shehzad Z Sheikh; Steven M Russo; Yoshiyuki Mishima; Colm Collins; Edwin F deZoeten; Christopher L Karp; Jenny P Y Ting; R Balfour Sartor; Scott E Plevy
Journal:  J Immunol       Date:  2012-07-11       Impact factor: 5.422

Review 3.  Biologic therapy for inflammatory bowel disease.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Changes of CD8+CD28- T regulatory cells in rat model of colitis induced by 2,4-dinitrofluorobenzene.

Authors:  Wen-Bin Xiao; Yu-Lan Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 5.  Current and emerging drugs for the treatment of inflammatory bowel disease.

Authors:  John K Triantafillidis; Emmanuel Merikas; Filippos Georgopoulos
Journal:  Drug Des Devel Ther       Date:  2011-04-06       Impact factor: 4.162

6.  α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease.

Authors:  Anastassios C Manolakis; Gregory Christodoulidis; Andreas N Kapsoritakis; Panagiotis Georgoulias; Elisavet K Tiaka; Kostas Oikonomou; Varvara J Valotassiou; Spyros P Potamianos
Journal:  World J Gastroenterol       Date:  2017-01-21       Impact factor: 5.742

7.  Biologic targeting in the treatment of inflammatory bowel diseases.

Authors:  Matteo Bosani; Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Biologics       Date:  2009-07-13

Review 8.  Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.

Authors:  Bruno Rafael Ramos de Mattos; Maellin Pereira Gracindo Garcia; Julia Bier Nogueira; Lisiery Negrini Paiatto; Cassia Galdino Albuquerque; Caique Lopes Souza; Luís Gustavo Romani Fernandes; Wirla Maria da Silva Cunha Tamashiro; Patricia Ucelli Simioni
Journal:  Mediators Inflamm       Date:  2015-08-03       Impact factor: 4.711
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.